Routine HIV screening in France: clinical impact and cost-effectiveness (Q28475837)

6

Dominique Costagliola

0 references

Caroline Semaille

5

Caroline Semaille

0 references

Stéphane Le Vu

Stéphane Le Vu

4

0 references

Rochelle P. Walensky

Rochelle P Walensky

12

0 references

Elena Losina

Elena Losina

11

0 references

Kenneth A. Freedberg

13

Kenneth A Freedberg

0 references

A. David Paltiel

14

A David Paltiel

0 references

Sylvie Deuffic-Burban

10

Sylvie Deuffic-Burban

0 references

Caroline E Sloan

2

Caroline E Sloan

0 references

author name string

Cécile Charlois-Ou

3

0 references

Josiane Pillonel

7

0 references

Anne-Isabelle Poullié

8

0 references

Olivier Scemama

Creative Commons Attribution 4.0 International

9

0 references

language of work or name

English

0 references

publication date

1 October 2010

0 references

published in

PLOS One

0 references

volume

5

0 references

issue

10

0 references

page(s)

e13132

0 references

copyright license

start time

1 October 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Late presenters in an HIV surveillance system in Italy during the period 1992-2006.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

HIV testing strategies across European countries.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Diagnosed and undiagnosed HIV-infected populations in Europe

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

The cost effectiveness of opportunistic chlamydia screening in England.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

The cost-effectiveness of expanded testing for primary HIV infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Building a model to determine the cost-effectiveness of breast cancer screening in France

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Opt-out testing for human immunodeficiency virus in the United States: progress and challenges

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

The estimation of a preference-based measure of health from the SF-12.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

The cost effectiveness of combination antiretroviral therapy for HIV disease.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956760

Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence

27 November 2018

1 reference

12 December 2020

Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models

1 reference

12 December 2020

Delayed Presentation and Late Testing for HIV: Demographic and Behavioral Risk Factors in a Multicenter Study in Italy

1 reference

12 December 2020

A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection

1 reference

12 December 2020

Frequency, determinants and consequences of delayed access to care for HIV infection in France

1 reference

12 December 2020